U.S. Markets close in 3 hrs 13 mins

LakePharma Initiates Key Technology Resource Networks

BELMONT, Calif., May 1, 2017 /PRNewswire/ -- LakePharma, the leading US-based biologics CRO, announced today the formation of two key technology resource networks.

LakePharma Antibody Technology Network (LATN) is an alliance of academic institutions and companies that provide technology access to LakePharma clients.  LakePharma will pre-negotiate competitive terms with each of the technology providers and pass those savings onto our clients.  Antibody technologies will include access to the following, but not limited to:

  • Antibody discovery platforms (in vivo and in vitro)
  • Novel bispecific constructs
  • Antibody drug conjugation (ADC) technologies
  • Antibody humanization technologies
  • Half-life extension technologies
  • Technologies to reduce antibody immunogenicity
  • Antibody stabilization technologies

To learn more, click here.

LakePharma Microbial Fermentation Network (LMFN) is an alliance of US-based institutions that provide microbial fermentation, downstream processing and testing to LakePharma clients. Expression hosts include Escherichia coli, Saccharomyces cerevisiae, and Pichia pastoris, which can be cultured from flask scale to 1000L bioreactors.

LMFN members include some of the top bioprocessing core labs in the US, and collectively possess enormous capacity, ranging from parallel batch process of hundreds of 3L shake flasks to 1000L bioreactors. In addition, sophisticated downstream processing, formulation, fill/finish, and release testing services, including GMP, are also offered.

To learn more, click here.

Aaron Sato, Ph. D., Chief Scientific Officer of LakePharma, commented: "These networks build upon our internal expertise in antibody development, protein production, analytical and functional assays, as well as market leadership and regulatory compliance expertise. Serving as the anchor of these networks, LakePharma provides end-to-end services to support research, process development, preclinical studies, and Phase I clinical trials.  Consistent with our vision, these networks will enable us to better serve our clients and provide them with the best technologies and capabilities in the industry."

About LakePharma

LakePharma is the leading contract research organization (CRO) specializing in antibody engineering, antibody discovery, molecular engineering, protein chemistry, bioexpression, biofunction, bioprocessing, and bioanalytics.  LakePharma focuses on integrated platforms to support projects throughout the drug discovery process. LakePharma offers dedicated client services and sophisticated software to provide real-time access to project data via a secure cloud-based portal. For more information, please visit lakepharma.com.

Walter Tian
VP Commercial Operation at LakePharma


To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lakepharma-initiates-key-technology-resource-networks-300449046.html